CONTENTS

ARTICLES


S Identification of Triterpene Acids in Poria cocos Extract as Bile Acid Uptake Transporter Inhibitors. Hui Cai, Yujie Cheng, Qiunan Zhu, Dexuan Kong, Xijing Chen, Ikumi Tamai, and Yang Lu ................................................................. 353

S The Long Noncoding RNA Hepatocyte Nuclear Factor 4z Antisense RNA 1 Negatively Regulates Cytochrome P450 Enzymes in Huh7 Cells via Histone Modifications. Pei Wang, Shitong Chen, Yiting Wang, Xiaofei Wang, Liang Yan, Kun Yang, Xiao-bo Zhong, Shengna Han, and Lirong Zhang ............................................................. 361


S Metabolic Retroversion of Piperaquine (PQ) via Hepatic Cytochrome P450–Mediated N-Oxidation and Reduction: Not an Important Contributor to the Prolonged Elimination of PQ. Yuewu Xie, Yunrui Zhang, Huixiang Liu, and Jie Xing .................. 379

S Clinical Investigation of Metabolic and Renal Clearance Pathways Contributing to the Elimination of Fevipiprant Using Probenecid as Perpetrator. H. Markus Weiss, Thomas Langenickel, Meredith Cain, Swarupa Kulkarni, Bharti Shah, Janardhana Vemula, Ghomamreza Rahmatzadeh, and Birk Poller ...................................................... 389


S Absorption, Metabolism, and Excretion, In Vitro Pharmacology, and Clinical Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Modulator. Sekhar Surapaneni, Usha Yerramilli, April Bai, Deepak Dalvie, Jennifer Brooks, Xiaomin Wang, Julie V. Selkirk, Yingzhuo Grace Yan, Peijin Zhang, Richard Hargreaves, Gondip Kumar, Maria Palmisano, and Jonathan Q. Tran ................................. 405

S Supplemental material is available online at http://dmd.aspetjournals.org.

About the cover: Drug disposition of fevipiprant (blue arrows) and the AG metabolite (AG met, dashed purple arrows) in humans based on in vitro phenotyping data (Pearson et al., 2017) and clinical study results. See the article by Weiss et al. (dx.doi.org/10.1124/dmd.120.000273).